LONDON (Alliance News) - ANGLE PLC said Monday that an evaluation of its Parsortix cell harvesting system has been published in the International Journal of Cancer.
The paper has been published by the University Medical Centre Hamburg-Eppendorf, Germany, and is in relation to the advantages of using Parsortix for the harvesting of circulating tumour cells in the blood compared to antibody-based and filtration circulating tumour cell enrichment systems.
"This is our third peer-reviewed publication in a key scientific journal and adds to the growing body of published evidence of Parsortix's superior performance as a liquid biopsy. The demonstration of viability of the CTCs is notable and in stark contrast to competing approaches," said Founder and Chief Executive Andrew Newland in a statement.
"Cell viability and easy harvesting of cells from blood are key capabilities that differentiate ANGLE's Parsortix system for the developing liquid biopsy market in cancer diagnosis and treatment," Newland added.
Shares in Angle were down 0.3% at 68.05 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Angle (AGL)